Richardson D S, Johnson S A, Hopkins J A, Howe D, Phillips M J
Department of Haematology, Taunton and Somerset Hospital, England.
Acta Oncol. 1994;33(6):627-30. doi: 10.3109/02841869409121773.
We report the results of assessment of minimal residual disease in four patients with chronic lymphocytic leukaemia, who achieved clinical and haematological complete response following treatment with fludarabine. Patients were assessed both before and after treatment by immunophenotyping, DNA electrophoresis, Southern blotting and PCR amplification to detect immunoglobulin gene rearrangements. Immediately after treatment, no patient had disease detectable by any method and there was evidence of recovery of normal B-cells. No patient has yet shown evidence of clinical or haematological relapse (follow-up 59-142 weeks). Two patients remain in immunophenotypic and molecular remission at 141 and 59 weeks. These methods have allowed more sensitive definition of elimination of residual disease, with PCR demonstrating the capacity to detect disease recurrence before any other evidence is available.
我们报告了4例慢性淋巴细胞白血病患者微小残留病的评估结果，这些患者在接受氟达拉滨治疗后达到了临床和血液学完全缓解。在治疗前后，通过免疫表型分析、DNA电泳、Southern印迹和PCR扩增来检测免疫球蛋白基因重排，对患者进行评估。治疗后立即进行检测，没有患者通过任何方法可检测到疾病，并且有证据表明正常B细胞已恢复。没有患者出现临床或血液学复发的迹象（随访59 - 142周）。两名患者在141周和59周时仍处于免疫表型和分子缓解状态。这些方法能够更敏感地定义残留病的清除情况，PCR显示出在任何其他证据出现之前检测疾病复发的能力。
